FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3099578333> ?p ?o ?g. }

• W3099578333 endingPage "314" @default.
• W3099578333 startingPage "303" @default.
• W3099578333 abstract "High levels of serum interleukin-6 (IL-6) correlate with disease severity in COVID-19. We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) could improve outcomes in selected patients with severe worsening COVID-19 pneumonia and high inflammatory parameters.The TOCICOVID study included a prospective cohort of patients aged 16-80 years with severe (requiring > 6 L/min of oxygen therapy to obtain Sp02 > 94%) rapidly deteriorating (increase by ≥ 3 L/min of oxygen flow within the previous 12 h) COVID-19 pneumonia with ≥ 5 days of symptoms and C-reactive protein levels > 40 mg/L. They entered a compassionate use program of treatment with intravenous tocilizumab (8 mg/kg with a maximum of 800 mg per infusion; and if needed a second infusion 24 to 72 h later). A control group was retrospectively selected with the same inclusion criteria. Outcomes were assessed at D28 using inverse probability of treatment weighted (IPTW) methodology.Among the 96 patients included (81% male, mean (SD) age: 60 (12.5) years), underlying conditions, baseline disease severity, and concomitant medications were broadly similar between the tocilizumab (n = 49) and the control (n = 47) groups. In the IPTW analysis, treatment with tocilizumab was associated with a reduced need for overall ventilatory support (49 vs. 89%, wHR: 0.39 [0.25-0.56]; p < 0.001). Albeit lacking statistical significance, there was a substantial trend towards a reduction of mechanical ventilation (31% vs. 45%; wHR: 0.58 [0.36-0.94]; p = 0.026). However, tocilizumab did not improve overall survival (wHR = 0.68 [0.31-1.748], p = 0.338). Among the 85 (89%) patients still alive at D28, patients treated with tocilizumab had a higher rate of oxygen withdrawal (82% vs. 73.5%, wHR = 1.66 [1.17-2.37], p = 0.005), with a shorter delay before being weaned of oxygen therapy (mean 11 vs. 16 days; p < 0.001). At D28, the rate of patients discharged from hospital was higher in the tocilizumab group (70% vs. 40%, wHR = 1.82 [1.22-2.75]; p = 0.003). The levels of CRP and fibrinogen post therapy (p < 0.001 for both variables) were significantly lower in the tocilizumab group (interaction test, mixed model). Rates of neutropenia (35% vs. 0%; p < 0.001) were higher in the tocilizumab group, yet rates of infections (22% vs. 38%, p = 0.089) including ventilator-acquired pneumonia (8% vs. 26%, p = 0.022) were higher in the control group.These data could be helpful for the design of future trials aiming to counter COVID-19-induced inflammation, especially before patients require admission to the intensive care unit." @default.
• W3099578333 created "2020-11-23" @default.
• W3099578333 creator A5002143109 @default.
• W3099578333 creator A5002364122 @default.
• W3099578333 creator A5003385416 @default.
• W3099578333 creator A5005491582 @default.
• W3099578333 creator A5006871103 @default.
• W3099578333 creator A5009410788 @default.
• W3099578333 creator A5015124748 @default.
• W3099578333 creator A5020497569 @default.
• W3099578333 creator A5021661813 @default.
• W3099578333 creator A5030023151 @default.
• W3099578333 creator A5030273471 @default.
• W3099578333 creator A5030711598 @default.
• W3099578333 creator A5037289997 @default.
• W3099578333 creator A5038981809 @default.
• W3099578333 creator A5041865172 @default.
• W3099578333 creator A5045482230 @default.
• W3099578333 creator A5046019705 @default.
• W3099578333 creator A5046887598 @default.
• W3099578333 creator A5048917531 @default.
• W3099578333 creator A5063466256 @default.
• W3099578333 creator A5064537418 @default.
• W3099578333 creator A5065430036 @default.
• W3099578333 creator A5068639395 @default.
• W3099578333 creator A5076182914 @default.
• W3099578333 creator A5080839939 @default.
• W3099578333 creator A5088530495 @default.
• W3099578333 creator A5088674853 @default.
• W3099578333 creator A5090912576 @default.
• W3099578333 date "2020-11-14" @default.
• W3099578333 modified "2023-10-04" @default.
• W3099578333 title "Tocilizumab for Severe Worsening COVID-19 Pneumonia: a Propensity Score Analysis" @default.
• W3099578333 cites W1761464837 @default.
• W3099578333 cites W2120801007 @default.
• W3099578333 cites W2733114572 @default.
• W3099578333 cites W3008090866 @default.
• W3099578333 cites W3009859788 @default.
• W3099578333 cites W3009885589 @default.
• W3099578333 cites W3011610993 @default.
• W3099578333 cites W3012379316 @default.
• W3099578333 cites W3012421327 @default.
• W3099578333 cites W3012422150 @default.
• W3099578333 cites W3016288338 @default.
• W3099578333 cites W3017400328 @default.
• W3099578333 cites W3018023298 @default.
• W3099578333 cites W3020168167 @default.
• W3099578333 cites W3021859907 @default.
• W3099578333 cites W3021915688 @default.
• W3099578333 cites W3022970339 @default.
• W3099578333 cites W3023088605 @default.
• W3099578333 cites W3023566105 @default.
• W3099578333 cites W3023606094 @default.
• W3099578333 cites W3025502129 @default.
• W3099578333 cites W3025972894 @default.
• W3099578333 cites W3026301261 @default.
• W3099578333 cites W3027630905 @default.
• W3099578333 cites W3030158388 @default.
• W3099578333 cites W3030325615 @default.
• W3099578333 cites W3035293132 @default.
• W3099578333 cites W3035822967 @default.
• W3099578333 cites W3036398841 @default.
• W3099578333 cites W3037784318 @default.
• W3099578333 cites W3038262515 @default.
• W3099578333 cites W3041464116 @default.
• W3099578333 cites W3048601848 @default.
• W3099578333 cites W3081721922 @default.
• W3099578333 cites W3081877184 @default.
• W3099578333 cites W3082108964 @default.
• W3099578333 cites W3082355253 @default.
• W3099578333 cites W3091337946 @default.
• W3099578333 cites W3110466220 @default.
• W3099578333 cites W3215360818 @default.
• W3099578333 cites W4210642183 @default.
• W3099578333 doi "https://doi.org/10.1007/s10875-020-00911-6" @default.
• W3099578333 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7666405" @default.
• W3099578333 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33188624" @default.
• W3099578333 hasPublicationYear "2020" @default.
• W3099578333 type Work @default.
• W3099578333 sameAs 3099578333 @default.
• W3099578333 citedByCount "36" @default.
• W3099578333 countsByYear W30995783332020 @default.
• W3099578333 countsByYear W30995783332021 @default.
• W3099578333 countsByYear W30995783332022 @default.
• W3099578333 countsByYear W30995783332023 @default.
• W3099578333 crossrefType "journal-article" @default.
• W3099578333 hasAuthorship W3099578333A5002143109 @default.
• W3099578333 hasAuthorship W3099578333A5002364122 @default.
• W3099578333 hasAuthorship W3099578333A5003385416 @default.
• W3099578333 hasAuthorship W3099578333A5005491582 @default.
• W3099578333 hasAuthorship W3099578333A5006871103 @default.
• W3099578333 hasAuthorship W3099578333A5009410788 @default.
• W3099578333 hasAuthorship W3099578333A5015124748 @default.
• W3099578333 hasAuthorship W3099578333A5020497569 @default.
• W3099578333 hasAuthorship W3099578333A5021661813 @default.
• W3099578333 hasAuthorship W3099578333A5030023151 @default.
• W3099578333 hasAuthorship W3099578333A5030273471 @default.
• W3099578333 hasAuthorship W3099578333A5030711598 @default.

• next